Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness and safety of lanadelumab (达泽优) and ecallantide (飞泽优) in hereditary angioedema in China
CTR20241595Phase 4Completed
- Sponsor
- Takeda
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of lanadelumab, ecallantide in hereditary angioedema (HAE), sponsored by Takeda. Started May 2024; status: completed.
02
Drugs
lanadelumabecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20241595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241595.